Avacta Life Sciences Limited
  • About
  • Therapeutics
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

News

21 Jul 2022

AffyXell Successfully Completes Funding Round

Investors | Therapeutics
30 Jun 2022

LG Chem renews license triggering payment to Avacta

Investors | Therapeutics
29 Jun 2022

Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin

Investors | Therapeutics
23 Jun 2022

Result of Annual General Meeting

Investors
31 May 2022

Posting of Annual Report and Notice of AGM

Investors
16 May 2022

AffyXell expands its strategic partnership with GenScript ProBio

Investors | Therapeutics
11 May 2022

Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus

Investors | Therapeutics
13 Apr 2022

AffyXell joint venture milestone and increased equity stake

Investors | Therapeutics
12 Apr 2022

Poster presented at the American Association for Cancer Research Annual Meeting available to download

Investors | Therapeutics
08 Apr 2022

AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center

Investors | Therapeutics

Posts navigation

Older posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

Investor Enquiries

FTI Consulting
200 Aldersgate
Aldersgate Street
London
EC1A 4HD

Email

Twitter | Linkedin

©2022 Avacta Life Sciences Limited. Registered company no. 06605196.